首页 > 最新文献

Molecular Imaging and Radionuclide Therapy最新文献

英文 中文
Care Pathway at a Cancer Center for the Administration of Radiometabolic Therapy with 177Lu-PSMA in Patients with Metastatic Castration-resistant Prostate Cancer. 癌症中心对转移性阉割抵抗性前列腺癌患者使用 177Lu-PSMA 进行放射代谢治疗的护理路径。
IF 0.9 Q3 Medicine Pub Date : 2024-02-22 DOI: 10.4274/mirt.galenos.2023.82653
Carlos Avila, Tatiana Cadavid, Maria Cristina Martínez, Humberto Varela, Nathalie Hernández-Hidalgo

Objectives: To present a clinical care model for the administration of 177Lu-labeled prostate-specific membrane antigen (PSMA) in radiometabolic therapy for metastatic castration-resistant prostate cancer (mCRPC) at the National Cancer Institute (NCI) of Bogotá, Colombia.

Methods: A care model was designed for patients with mCRPC based on the VISION study, a prospective, phase III, multicenter, open-label, randomized study in patients with positive 68Ga-PSMA positron emission tomography/computed tomography who had progressed to taxane and androgen therapy, to receive 177Lu-PSMA-617 combined with the best standard of care vs. the best standard of care alone. The care pathway provided to patients was developed by the Nuclear Medicine Group of the NCI and is the result of adjustments and improvements in the care process and the updating of the literature.

Results: A systematic and efficient care model was formalized and implemented for the administration of 177Lu-PSMA therapy in patients with mCRPC who had previously been treated with at least one androgen receptor pathway inhibitor and one or two taxane regimens, with evidence of disease progression.

Conclusion: An optimized process of care based on the determinants of clinical outcomes was developed for patients who received this type of radiometabolic therapy.

目的:介绍哥伦比亚波哥大国家癌症研究所(NCI)在转移性去势抵抗性前列腺癌(mCRPC)的放射代谢治疗中应用177Lu标记的前列腺特异性膜抗原(PSMA)的临床护理模式:VISION研究是一项前瞻性、III期、多中心、开放标签、随机研究,对象是68Ga-PSMA正电子发射断层扫描/计算机断层扫描呈阳性、接受过紫杉类药物和雄激素治疗后病情恶化的mCRPC患者,研究人员根据VISION研究设计了一种护理模式,让患者接受177Lu-PSMA-617联合最佳标准疗法与单独最佳标准疗法的治疗。为患者提供的护理路径由 NCI 核医学小组制定,是护理流程调整和改进以及文献更新的结果:结果:对于既往接受过至少一种雄激素受体通路抑制剂和一种或两种类固醇类药物治疗并有疾病进展证据的mCRPC患者,正式确定并实施了一种系统、高效的177Lu-PSMA治疗护理模式:根据临床疗效的决定因素,为接受这种放射代谢疗法的患者制定了优化的治疗流程。
{"title":"Care Pathway at a Cancer Center for the Administration of Radiometabolic Therapy with 177Lu-PSMA in Patients with Metastatic Castration-resistant Prostate Cancer.","authors":"Carlos Avila, Tatiana Cadavid, Maria Cristina Martínez, Humberto Varela, Nathalie Hernández-Hidalgo","doi":"10.4274/mirt.galenos.2023.82653","DOIUrl":"10.4274/mirt.galenos.2023.82653","url":null,"abstract":"<p><strong>Objectives: </strong>To present a clinical care model for the administration of 177Lu-labeled prostate-specific membrane antigen (PSMA) in radiometabolic therapy for metastatic castration-resistant prostate cancer (mCRPC) at the National Cancer Institute (NCI) of Bogotá, Colombia.</p><p><strong>Methods: </strong>A care model was designed for patients with mCRPC based on the VISION study, a prospective, phase III, multicenter, open-label, randomized study in patients with positive <sup>68</sup>Ga-PSMA positron emission tomography/computed tomography who had progressed to taxane and androgen therapy, to receive 177Lu-PSMA-617 combined with the best standard of care vs. the best standard of care alone. The care pathway provided to patients was developed by the Nuclear Medicine Group of the NCI and is the result of adjustments and improvements in the care process and the updating of the literature.</p><p><strong>Results: </strong>A systematic and efficient care model was formalized and implemented for the administration of 177Lu-PSMA therapy in patients with mCRPC who had previously been treated with at least one androgen receptor pathway inhibitor and one or two taxane regimens, with evidence of disease progression.</p><p><strong>Conclusion: </strong>An optimized process of care based on the determinants of clinical outcomes was developed for patients who received this type of radiometabolic therapy.</p>","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":"33 1","pages":"28-37"},"PeriodicalIF":0.9,"publicationDate":"2024-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10899736/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139933420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Added-value of Staging 18F-FDG PET/CT in the Prediction of Overall Survival in the Patients with Bladder Cancer. 分期 18F-FDG PET/CT 在预测膀胱癌患者总生存期中的附加值
IF 0.9 Q3 Medicine Pub Date : 2024-02-22 DOI: 10.4274/mirt.galenos.2023.65002
Seda Gülbahar Ateş, Bedriye Büşra Demirel, Halil Başar, Gülin Uçmak

Objectives: This retrospective study aimed to evaluate the prognostic importance of 18F-fluorodeoxyglucose (18F-FDG)-positive pelvic lymph nodes (LNs) and extra-pelvic disease on staging 18F-FDG positron emission tomography/computed tomography (PET/CT) in patients with bladder cancer.

Methods: Bladder cancer patients who underwent staging 18F-FDG PET/CT were included in the study. Histopathologic features of tumors, therapy histories, presence of distinguishable tumors on CT and PET images, sizes and maximum standardized uptake value (SUVmax) of primary tumors, total numbers, sizes, and SUVmax of 18F-FDG-positive pelvic and extra-pelvic LNs, and total numbers and SUVmax of distant metastases (M1a/1b) were recorded. Patients were followed up until death or the last medical visit. Factors predicting overall survival were determined using Cox regression analysis.

Results: Fifty-five patients [median age: 70 (53-84), 48 (87.3%) male, 7 (12.7%) female] with bladder cancer were included in this study. Twenty-nine (52.7%) patients had 18F-FDG positive pelvic LNs, while 24 (43.7%) patients had 18F-FDG positive extra-pelvic disease. Patients with 18F-FDGpositive pelvic LNs had a higher rate of extra-pelvic disease (p=0.003). The median follow-up duration was 13.5 months. The median overall survival was 16.3 months [95% confidence interval (CI) 8.9-23.7]. The primary tumor distinguishability on PET (p=0.011) and CT (p=0.009) images, the presence of 18F-FDG-positive pelvic LNs (p<0.001) and 18F-FDG-positive extra-pelvic disease/distant metastases (M1a/M1b) (p<0.001), and the number of distant metastases (p=0.034) were associated with mortality. The 18F-FDG-positive extra-pelvic disease/distant metastases [p=0.029, odds ratio: 4.15 (95% CI 1.16-14.86)] was found to be an independent predictor of mortality in patients with bladder cancer.

Conclusion: The presence of 18F-FDG-positive extra-pelvic disease in pretreatment 18F-FDG PET/CT is an important prognostic factor in bladder cancer patients.

研究目的这项回顾性研究旨在评估18F-氟脱氧葡萄糖(18F-FDG)阳性盆腔淋巴结(LN)和盆腔外疾病对膀胱癌患者分期18F-FDG正电子发射断层扫描/计算机断层扫描(PET/CT)预后的重要性:研究对象包括接受分期 18F-FDG PET/CT 检查的膀胱癌患者。记录肿瘤的组织病理学特征、治疗史、CT 和 PET 图像上可分辨的肿瘤、原发肿瘤的大小和最大标准化摄取值(SUVmax)、18F-FDG 阳性盆腔和盆腔外 LN 的总数、大小和 SUVmax,以及远处转移灶(M1a/1b)的总数和 SUVmax。对患者进行随访,直至死亡或最后一次就诊。采用Cox回归分析确定预测总生存率的因素:本研究共纳入55名膀胱癌患者[中位年龄:70(53-84)岁,48(87.3%)名男性,7(12.7%)名女性]。29例(52.7%)患者的盆腔LN呈18F-FDG阳性,24例(43.7%)患者的盆腔外疾病呈18F-FDG阳性。18F-FDG 阳性盆腔 LN 患者的盆腔外疾病发生率更高(P=0.003)。中位随访时间为13.5个月。中位总生存期为 16.3 个月[95% 置信区间 (CI) 8.9-23.7]。PET(p=0.011)和CT(p=0.009)图像上的原发肿瘤可分辨性、18F-FDG阳性盆腔LN(p18F-FDG阳性盆腔外疾病/远处转移灶(M1a/M1b)(p18F-FDG阳性盆腔外疾病/远处转移灶 [p=0.029, odds ratio: 4.15 (95% CI 1.16-14.86)] 是膀胱癌患者死亡率的独立预测因素:结论:治疗前 18F-FDG PET/CT 中出现 18F-FDG 阳性的盆腔外疾病是膀胱癌患者的一个重要预后因素。
{"title":"The Added-value of Staging <sup>18</sup>F-FDG PET/CT in the Prediction of Overall Survival in the Patients with Bladder Cancer.","authors":"Seda Gülbahar Ateş, Bedriye Büşra Demirel, Halil Başar, Gülin Uçmak","doi":"10.4274/mirt.galenos.2023.65002","DOIUrl":"10.4274/mirt.galenos.2023.65002","url":null,"abstract":"<p><strong>Objectives: </strong>This retrospective study aimed to evaluate the prognostic importance of <sup>18</sup>F-fluorodeoxyglucose (<sup>18</sup>F-FDG)-positive pelvic lymph nodes (LNs) and extra-pelvic disease on staging <sup>18</sup>F-FDG positron emission tomography/computed tomography (PET/CT) in patients with bladder cancer.</p><p><strong>Methods: </strong>Bladder cancer patients who underwent staging <sup>18</sup>F-FDG PET/CT were included in the study. Histopathologic features of tumors, therapy histories, presence of distinguishable tumors on CT and PET images, sizes and maximum standardized uptake value (SUV<sub>max</sub>) of primary tumors, total numbers, sizes, and SUV<sub>max</sub> of <sup>18</sup>F-FDG-positive pelvic and extra-pelvic LNs, and total numbers and SUV<sub>max</sub> of distant metastases (M1a/1b) were recorded. Patients were followed up until death or the last medical visit. Factors predicting overall survival were determined using Cox regression analysis.</p><p><strong>Results: </strong>Fifty-five patients [median age: 70 (53-84), 48 (87.3%) male, 7 (12.7%) female] with bladder cancer were included in this study. Twenty-nine (52.7%) patients had <sup>18</sup>F-FDG positive pelvic LNs, while 24 (43.7%) patients had <sup>18</sup>F-FDG positive extra-pelvic disease. Patients with <sup>18</sup>F-FDGpositive pelvic LNs had a higher rate of extra-pelvic disease (p=0.003). The median follow-up duration was 13.5 months. The median overall survival was 16.3 months [95% confidence interval (CI) 8.9-23.7]. The primary tumor distinguishability on PET (p=0.011) and CT (p=0.009) images, the presence of <sup>18</sup>F-FDG-positive pelvic LNs (p<0.001) and <sup>18</sup>F-FDG-positive extra-pelvic disease/distant metastases (M1a/M1b) (p<0.001), and the number of distant metastases (p=0.034) were associated with mortality. The <sup>18</sup>F-FDG-positive extra-pelvic disease/distant metastases [p=0.029, odds ratio: 4.15 (95% CI 1.16-14.86)] was found to be an independent predictor of mortality in patients with bladder cancer.</p><p><strong>Conclusion: </strong>The presence of <sup>18</sup>F-FDG-positive extra-pelvic disease in pretreatment <sup>18</sup>F-FDG PET/CT is an important prognostic factor in bladder cancer patients.</p>","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":"33 1","pages":"11-18"},"PeriodicalIF":0.9,"publicationDate":"2024-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10899737/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139933426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bone and Parathyroid Scintigraphy Findings in Sagliker Syndrome. 萨格里克综合征的骨骼和甲状旁腺闪烁扫描结果
IF 0.9 Q3 Medicine Pub Date : 2024-02-22 DOI: 10.4274/mirt.galenos.2023.24382
Çağlagül Erol, Özlem Şahin, Ahmet Eren Şen, Zeynep Aydın

Sagliker syndrome (SS) is a rare, exaggerated form of chronic kidney disease (CKD)-mineral and bone disorder resulting from untreated secondary hyperparathyroidism due to CKD. Herein, we describe a 34-year-old male patient whose Tc-99m-methylene diphosphonate bone scintigraphy and Tc-99m-sestamibi parathyroid scintigraphy revealed hints of SS and exhibited its defining characteristics.

萨格利克综合征(Sagliker syndrome,SS)是慢性肾脏病(CKD)的一种罕见、夸张的矿物质和骨骼疾病,由于CKD引起的继发性甲状旁腺功能亢进症未经治疗而导致。在这里,我们描述了一名34岁的男性患者,他的Tc-99m-亚甲基二膦酸盐骨闪烁扫描和Tc-99m-sestamibi甲状旁腺闪烁扫描显示出了SS的蛛丝马迹,并表现出了SS的特征。
{"title":"Bone and Parathyroid Scintigraphy Findings in Sagliker Syndrome.","authors":"Çağlagül Erol, Özlem Şahin, Ahmet Eren Şen, Zeynep Aydın","doi":"10.4274/mirt.galenos.2023.24382","DOIUrl":"10.4274/mirt.galenos.2023.24382","url":null,"abstract":"<p><p>Sagliker syndrome (SS) is a rare, exaggerated form of chronic kidney disease (CKD)-mineral and bone disorder resulting from untreated secondary hyperparathyroidism due to CKD. Herein, we describe a 34-year-old male patient whose Tc-99m-methylene diphosphonate bone scintigraphy and Tc-99m-sestamibi parathyroid scintigraphy revealed hints of SS and exhibited its defining characteristics.</p>","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":"33 1","pages":"40-42"},"PeriodicalIF":0.9,"publicationDate":"2024-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10899744/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139933419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Testicular Incidentaloma on 18F-choline PET/CT in a Patient with Prostatic Adenocarcinoma 一名前列腺腺癌患者的 18F-choline PET/CT 检出睾丸偶发瘤
IF 0.9 Q3 Medicine Pub Date : 2024-02-20 DOI: 10.4274/mirt.galenos.2024.76259
Chaymae Bensaid, Salah Oueriagli Nabih, Meryem Aboussabr, O. Sahel, Y. Benameur, A. Doudouh
Prostatic adenocarcinoma is characterized by elevated phosphatidylcholine metabolism. 18 F-choline positron emission tomography/computed tomography (PET/CT) is widely used for patients with biochemical recurrence and a prostate-specific antigen threshold above 2 ng/mL. We report a case of a patient with high-risk prostatic adenocarcinoma undergoing 18 F-choline PET/CT for biochemical recurrence. In addition to hypermetabolic abdominal lymph nodes, an unexpected right testicular hypermetabolism was observed. Such findings on 18 F-choline PET/CT may suggest a primary tumor or testicular metastasis of prostate cancer. Bilateral orchiectomy revealed a vitelline tumor associated with known primary prostatic cancer. The incidental discovery of a testicular vitelline tumor during prostate cancer imaging is rare, highlighting the importance of thorough diagnostics. This case underscores the need for comprehensive care in managing complex and atypical cancer cases, emphasizing the potential for unrelated tumor discoveries during diagnostic workup. Further research is essential for a better understanding of these rare co-occurring cancers and their treatment implications
前列腺腺癌的特点是磷脂酰胆碱代谢升高。18 F-胆碱正电子发射断层扫描/计算机断层扫描(PET/CT)被广泛用于生化复发且前列腺特异性抗原阈值高于 2 ng/mL 的患者。我们报告了一例因生化复发而接受 18 F-choline PET/CT 检查的高危前列腺腺癌患者。除了腹部淋巴结高代谢外,还意外观察到右侧睾丸高代谢。18 F-choline PET/CT 上的这种发现可能提示原发肿瘤或前列腺癌的睾丸转移。双侧睾丸切除术发现了一个与已知原发性前列腺癌相关的玻璃体肿瘤。在前列腺癌成像过程中意外发现睾丸玻璃体瘤的情况非常罕见,这凸显了彻底诊断的重要性。该病例强调,在处理复杂和不典型的癌症病例时,需要进行全面护理,并强调在诊断工作中发现无关肿瘤的可能性。为了更好地了解这些罕见的并发癌症及其对治疗的影响,进一步的研究是必不可少的。
{"title":"Testicular Incidentaloma on 18F-choline PET/CT in a Patient with Prostatic Adenocarcinoma","authors":"Chaymae Bensaid, Salah Oueriagli Nabih, Meryem Aboussabr, O. Sahel, Y. Benameur, A. Doudouh","doi":"10.4274/mirt.galenos.2024.76259","DOIUrl":"https://doi.org/10.4274/mirt.galenos.2024.76259","url":null,"abstract":"Prostatic adenocarcinoma is characterized by elevated phosphatidylcholine metabolism. 18 F-choline positron emission tomography/computed tomography (PET/CT) is widely used for patients with biochemical recurrence and a prostate-specific antigen threshold above 2 ng/mL. We report a case of a patient with high-risk prostatic adenocarcinoma undergoing 18 F-choline PET/CT for biochemical recurrence. In addition to hypermetabolic abdominal lymph nodes, an unexpected right testicular hypermetabolism was observed. Such findings on 18 F-choline PET/CT may suggest a primary tumor or testicular metastasis of prostate cancer. Bilateral orchiectomy revealed a vitelline tumor associated with known primary prostatic cancer. The incidental discovery of a testicular vitelline tumor during prostate cancer imaging is rare, highlighting the importance of thorough diagnostics. This case underscores the need for comprehensive care in managing complex and atypical cancer cases, emphasizing the potential for unrelated tumor discoveries during diagnostic workup. Further research is essential for a better understanding of these rare co-occurring cancers and their treatment implications","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":"285 ","pages":""},"PeriodicalIF":0.9,"publicationDate":"2024-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140448136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Late 68Ga PSMA-positive Pancreatic Metastasis From Renal Cell Carcinoma in a Patient with Metastatic Prostate Cancer: A Mission Impossible 转移性前列腺癌患者肾细胞癌晚期 68Ga PSMA 阳性胰腺转移:不可能完成的任务
IF 0.9 Q3 Medicine Pub Date : 2024-02-19 DOI: 10.4274/mirt.galenos.2023.90582
Gabriela Mateva, Nikolina Novoselska, Assen Dudov, Marina Garcheva-Tsacheva, Pavel Bochev
{"title":"Late 68Ga PSMA-positive Pancreatic Metastasis From Renal Cell Carcinoma in a Patient with Metastatic Prostate Cancer: A Mission Impossible","authors":"Gabriela Mateva, Nikolina Novoselska, Assen Dudov, Marina Garcheva-Tsacheva, Pavel Bochev","doi":"10.4274/mirt.galenos.2023.90582","DOIUrl":"https://doi.org/10.4274/mirt.galenos.2023.90582","url":null,"abstract":"","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":"12 1","pages":""},"PeriodicalIF":0.9,"publicationDate":"2024-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139958773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnosis and Evaluation of Treatment Response in Relapsing Polychondritis Using 18F-FDG PET/CT 利用 18F-FDG PET/CT 诊断和评估复发性多软骨炎的治疗反应
IF 0.9 Q3 Medicine Pub Date : 2024-02-19 DOI: 10.4274/mirt.galenos.2023.80958
Caner Civan, E. Isik, Duygu Has Şimşek, Mustafa Altınkaynak, S. Kuyumcu
A 58-year-old man presenting with dyspnea, weight loss, and night sweating underwent 18 F-fluorodeoxyglucose positron emission tomography/ computed tomography ( 18 F-FDG PET/CT) because of a suspicion of malignancy. 18 F-FDG PET/CT demonstrated mild to moderate uptake on nasal, cricoid, and tracheobronchial tree cartilages and costovertebral junctions. The diagnosis was relapsing polychondritis, which is a rare multisystem disease characterized by inflammation of cartilage. In addition, subsequent 18 F-FDG PET/CT after treatment showed complete metabolic response.
一名 58 岁男子因怀疑患有恶性肿瘤,出现呼吸困难、体重减轻和盗汗症状,接受了 18 F-FDG 正电子发射/计算机断层扫描(18 F-FDG PET/CT)检查。18 F-FDG PET/CT 显示鼻腔、环状软骨、气管支气管软骨和肋椎交界处有轻度至中度摄取。诊断结果为复发性多软骨炎,这是一种罕见的以软骨炎症为特征的多系统疾病。此外,治疗后的18 F-FDG PET/CT显示完全代谢反应。
{"title":"Diagnosis and Evaluation of Treatment Response in Relapsing Polychondritis Using 18F-FDG PET/CT","authors":"Caner Civan, E. Isik, Duygu Has Şimşek, Mustafa Altınkaynak, S. Kuyumcu","doi":"10.4274/mirt.galenos.2023.80958","DOIUrl":"https://doi.org/10.4274/mirt.galenos.2023.80958","url":null,"abstract":"A 58-year-old man presenting with dyspnea, weight loss, and night sweating underwent 18 F-fluorodeoxyglucose positron emission tomography/ computed tomography ( 18 F-FDG PET/CT) because of a suspicion of malignancy. 18 F-FDG PET/CT demonstrated mild to moderate uptake on nasal, cricoid, and tracheobronchial tree cartilages and costovertebral junctions. The diagnosis was relapsing polychondritis, which is a rare multisystem disease characterized by inflammation of cartilage. In addition, subsequent 18 F-FDG PET/CT after treatment showed complete metabolic response.","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":"44 14","pages":""},"PeriodicalIF":0.9,"publicationDate":"2024-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140451970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unusual Soft Tissue Uptake of Tc-99m MDP in Radiation-induced Sarcoma: Diagnostic Conundrum 放射性肉瘤对 Tc-99m MDP 的异常软组织摄取:诊断难题
IF 0.9 Q3 Medicine Pub Date : 2024-02-19 DOI: 10.4274/mirt.galenos.2023.58224
Sharjeel Usmani, Anjali Jain, K. Riyami, Zahida Niaz, S. Kheruka, Vipin V Jayakrishnan
{"title":"Unusual Soft Tissue Uptake of Tc-99m MDP in Radiation-induced Sarcoma: Diagnostic Conundrum","authors":"Sharjeel Usmani, Anjali Jain, K. Riyami, Zahida Niaz, S. Kheruka, Vipin V Jayakrishnan","doi":"10.4274/mirt.galenos.2023.58224","DOIUrl":"https://doi.org/10.4274/mirt.galenos.2023.58224","url":null,"abstract":"","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":"121 ","pages":""},"PeriodicalIF":0.9,"publicationDate":"2024-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140451808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Jejunal Undifferentiated Spindle Cell Sarcoma with Intussusception Revealed by 18F-FDG PET/CT 18F-FDG PET/CT 揭示的伴有肠套叠的空肠未分化纺锤形细胞肉瘤
IF 0.9 Q3 Medicine Pub Date : 2024-02-19 DOI: 10.4274/mirt.galenos.2023.99810
Haiyan Li, Xia Lu
{"title":"Jejunal Undifferentiated Spindle Cell Sarcoma with Intussusception Revealed by 18F-FDG PET/CT","authors":"Haiyan Li, Xia Lu","doi":"10.4274/mirt.galenos.2023.99810","DOIUrl":"https://doi.org/10.4274/mirt.galenos.2023.99810","url":null,"abstract":"","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":"5 2","pages":""},"PeriodicalIF":0.9,"publicationDate":"2024-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139958540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An Uncommon Case of Pediatric Nasopharyngeal Carcinoma with Bone Metastases and Enchondromas Evaluated Using 18F-FDG PET/CT 使用 18F-FDG PET/CT 评估小儿鼻咽癌伴骨转移和软骨瘤的罕见病例
IF 0.9 Q3 Medicine Pub Date : 2024-02-19 DOI: 10.4274/mirt.galenos.2023.69672
N. Quartuccio, Salvatore Ialuna, Salvatore Poma, V. L. Lentini, Alessandro Pitruzzella, Giuseppe Mario Galfano, Antonino Maria Moreci, D. Modica
{"title":"An Uncommon Case of Pediatric Nasopharyngeal Carcinoma with Bone Metastases and Enchondromas Evaluated Using 18F-FDG PET/CT","authors":"N. Quartuccio, Salvatore Ialuna, Salvatore Poma, V. L. Lentini, Alessandro Pitruzzella, Giuseppe Mario Galfano, Antonino Maria Moreci, D. Modica","doi":"10.4274/mirt.galenos.2023.69672","DOIUrl":"https://doi.org/10.4274/mirt.galenos.2023.69672","url":null,"abstract":"","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":"15 2","pages":""},"PeriodicalIF":0.9,"publicationDate":"2024-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140450613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
18F-FDG and 68Ga-FAPI-04 PET/CT Findings of a Rare Epithelialmyoepithelial Carcinoma Arising From Ex Pleomorphic Adenoma of Parotid 18F-FDG和68Ga-FAPI-04 PET/CT发现腮腺前多形腺瘤引发的罕见上皮上皮癌
IF 0.9 Q3 Medicine Pub Date : 2024-02-19 DOI: 10.4274/mirt.galenos.2023.83435
Caner Civan, Duygu Has Şimşek, Dogu Vuralli Bakkaloglu, S. Kuyumcu
{"title":"18F-FDG and 68Ga-FAPI-04 PET/CT Findings of a Rare Epithelialmyoepithelial Carcinoma Arising From Ex Pleomorphic Adenoma of Parotid","authors":"Caner Civan, Duygu Has Şimşek, Dogu Vuralli Bakkaloglu, S. Kuyumcu","doi":"10.4274/mirt.galenos.2023.83435","DOIUrl":"https://doi.org/10.4274/mirt.galenos.2023.83435","url":null,"abstract":"","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":"24 15","pages":""},"PeriodicalIF":0.9,"publicationDate":"2024-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140450453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Molecular Imaging and Radionuclide Therapy
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1